STOCK TITAN

Lantern Pharma Inc - LTRN STOCK NEWS

Welcome to our dedicated news page for Lantern Pharma (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lantern Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lantern Pharma's position in the market.

Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) will host its third quarter 2023 operating and financial results webcast on November 8th at 4:30 p.m. ET. The company will discuss the operating and financial results for the third quarter, as well as provide guidance on upcoming milestones, clinical trials, and developments of its AI platform, RADR®. The webcast will be led by Panna Sharma, President and CEO of Lantern Pharma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
conferences earnings
-
Rhea-AI Summary
Lantern Pharma Inc. to present at ThinkEquity Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.32%
Tags
conferences
-
Rhea-AI Summary
Lantern Pharma announces in vivo data on drug candidate LP-184 in glioblastoma, validating its potential as a therapeutic for GBM. Phase 1 trial underway. LP-184 has a global market potential of $11-13 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.23%
Tags
none
Rhea-AI Summary
Lantern Pharma announces dosing of first patient in Phase 1 trial for LP-184, a potential therapy for advanced solid tumors and CNS cancers. LP-184 has a global market potential of $11-13 billion. Multiple clinical trial sites to be activated in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.84%
Tags
-
Rhea-AI Summary
Lantern Pharma receives FDA clearance for LP-284 IND application, a drug candidate for non-Hodgkin's lymphoma, with a potential market value of $4 billion USD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
-
Rhea-AI Summary
Lantern Pharma to present positive data on its drug candidate LP-284 for non-Hodgkin’s lymphoma at SOHO Annual Meeting. Phase 1 clinical trials expected to start in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.64%
Tags
conferences
Rhea-AI Summary
Lantern Pharma expands RADR® platform for improved immune checkpoint inhibitor (ICI) drug development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
-
Rhea-AI Summary
Lantern Pharma announces operational highlights and financial results for Q2 2023, including FDA clearance for LP-184 and completion of IND-enabling studies for LP-284. Cash runway until 2025 with $48.0 million in cash, cash equivalents, and marketable securities. Collaboration with Bielefeld University for ADC development. LP-184 Phase 1 trial targeting relapsed/refractory advanced solid tumors and brain cancers. LP-284 Phase 1 trial targeted for Q4 in advanced non-Hodgkin’s lymphomas. Phase 2 trial for LP-300 in never smokers with NSCLC. Patent allowance for LP-284 extending commercial protection until early 2039.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.07%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
conferences earnings
Lantern Pharma Inc

Nasdaq:LTRN

LTRN Rankings

LTRN Stock Data

68.64M
7.86M
15.06%
22.49%
3.92%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Dallas

About LTRN

lantern pharma is leading a wave of innovation in cancer treatment that we believe will bring the best therapies to patients who are most likely to respond. we are pioneering precision medicine approach to cancer by tailoring promising drug programs to the right patients. our approach is to use biomarker based genetic screening to identify and treat patients that would benefit most from our drugs. we believe this approach will reduce the cost of development and increase the speed to market. our strategy is to acquire or partner with promising drug and diagnostic companies to move forward promising personalized medicine programs for cancer patients.